Otsuka takes up Lundbeck's Alzheimer's candidate
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has gained co-development and co-commercialization rights in selected markets to Lundbeck's 5HT6 receptor antagonist for Alzheimer's disease Lu AE58054, in a deal that marks a further expansion of the global CNS alliance between the two firms.